Le Lézard11h
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...
BioSpace3d
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
Medscape6d
The Hypoxic Tumor Microenvironment: Driving the Tumorigenesis of Non-small-cell Lung Cancer
non-small-cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC can be further subdivided into: lung adenocarcinoma (ADC), large cell carcinoma and squamous cell carcinoma (SCC).
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025- Completed ...
TipRanks on MSN4d
Immutep Reports Increased Revenue Amid Growing R&D Costs
Immutep ( ($IMMP) ) has released its Q2 earnings. Here is a breakdown of the information Immutep presented to its investors. Immutep Limited is a ...